Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genmab Ready For European Zalutumumab Filing Based On PFS Data, Searching For A Partner To Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

Indications are a regulatory filing for the EGFR inhibitor in second-line head and neck cancer would be acceptable in Europe, though not in the U.S., CEO vande Winkel says.

You may also be interested in...



Janssen Boosts Multiple Myeloma R&D With Genmab Deal

Janssen Biotech has signed its second deal in less than two months with antibody discovery company Genmab, this time licensing the Danish company's potential first-in-class multiple myeloma therapy daratumumab for $55 million upfront and an equity investment.

Genmab Reins In, Looks To Partners

Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.

Genmab Reins In, Looks To Partners

Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel